Skip to main content
icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Tech·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Tech·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

13% chance
Polymarket

$11,314 Vol.

13% chance
Polymarket

$11,314 Vol.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing collaboration with Peptron remains limited to a non-binding evaluation agreement signed in October 2024, under which the pharma giant received only a non-exclusive license to test SmartDepot’s ultrasonic spray-dried PLGA microsphere sustained-release platform on select peptides for internal R&D. The original 14-month term was extended to a maximum of 24 months ending October 7, 2026, yet no commercial technology-transfer or licensing deal has materialized despite preclinical data sharing and scope expansion into CNS applications. Lilly’s parallel pursuit of alternative long-acting delivery systems, such as Camurus’ FluidCrystal technology for incretin candidates, has further signaled no imminent commitment. With weeks remaining before resolution and no binding announcement, trader capital reflects strong skepticism that a definitive license will close in time.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,314
Date de fin
7 oct. 2026
Marché ouvert
May 5, 2026, 8:02 PM ET

Résolveur

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing collaboration with Peptron remains limited to a non-binding evaluation agreement signed in October 2024, under which the pharma giant received only a non-exclusive license to test SmartDepot’s ultrasonic spray-dried PLGA microsphere sustained-release platform on select peptides for internal R&D. The original 14-month term was extended to a maximum of 24 months ending October 7, 2026, yet no commercial technology-transfer or licensing deal has materialized despite preclinical data sharing and scope expansion into CNS applications. Lilly’s parallel pursuit of alternative long-acting delivery systems, such as Camurus’ FluidCrystal technology for incretin candidates, has further signaled no imminent commitment. With weeks remaining before resolution and no binding announcement, trader capital reflects strong skepticism that a definitive license will close in time.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,314
Date de fin
7 oct. 2026
Marché ouvert
May 5, 2026, 8:02 PM ET

Résolveur

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.

Connexes

icon for Demande de licence de vaccin contre le cancer de la peau soumise avant le 30 juin 2027 ?

Demande de licence de vaccin contre le cancer de la peau soumise avant le 30 juin 2027 ?

88%
Oui
icon for La FDA approuve-t-elle le Rétatrutide cette année ?

La FDA approuve-t-elle le Rétatrutide cette année ?

2%
Oui
icon for Vaccin contre le cancer de la peau approuvé par la FDA d'ici le 31 décembre 2027 ?

Vaccin contre le cancer de la peau approuvé par la FDA d'ici le 31 décembre 2027 ?

68%
Oui

Méfiez-vous des liens externes.

Questions fréquentes

« Eli Lilly licenses Peptron’s SmartDepot by October 7? » est un marché de prédiction sur Polymarket où les traders achètent et vendent des parts « Oui » ou « Non » selon qu'ils estiment que cet événement se produira ou non. La probabilité actuelle selon la communauté est de 13% pour « Yes ». Par exemple, si « Oui » est coté à 13¢, le marché attribue collectivement une probabilité de 13% que cet événement se produise. Ces cotes changent en permanence à mesure que les traders réagissent aux nouveaux développements et informations. Les parts du résultat correct sont échangeables contre $1 chacune lors de la résolution du marché.

À ce jour, « Eli Lilly licenses Peptron’s SmartDepot by October 7? » a généré $11.3K en volume total de trading depuis le lancement du marché le May 5, 2026. Ce niveau d'activité reflète un fort engagement de la communauté Polymarket et garantit que les cotes actuelles sont alimentées par un large bassin de participants. Vous pouvez suivre les mouvements de prix en direct et trader sur n'importe quel résultat directement sur cette page.

Pour trader sur « Eli Lilly licenses Peptron’s SmartDepot by October 7? », choisissez simplement si vous pensez que la réponse est « Oui » ou « Non ». Chaque côté a un prix actuel qui reflète la probabilité implicite du marché. Entrez votre montant et cliquez sur « Trader ». Si vous achetez des parts « Oui » et que le résultat se résout comme « Oui », chaque part rapporte $1. S'il se résout comme « Non », vos parts « Oui » rapportent $0. Vous pouvez également vendre vos parts à tout moment avant la résolution pour sécuriser un gain ou limiter une perte.

La probabilité actuelle pour « Eli Lilly licenses Peptron’s SmartDepot by October 7? » est de 13% pour « Yes ». Cela signifie que la communauté Polymarket estime actuellement qu'il y a une probabilité de 13% que cet événement se produise. Ces cotes sont mises à jour en temps réel sur la base de transactions réelles, fournissant un signal continuellement actualisé de ce que le marché attend.

Les règles de résolution de « Eli Lilly licenses Peptron’s SmartDepot by October 7? » définissent exactement ce qui doit se produire pour que chaque résultat soit déclaré gagnant, y compris les sources de données officielles utilisées pour déterminer le résultat. Vous pouvez consulter les critères de résolution complets dans la section « Règles » sur cette page au-dessus des commentaires. Nous recommandons de lire attentivement les règles avant de trader, car elles précisent les conditions exactes, les cas particuliers et les sources.